Tags : Under

Pfizer Initiates Clinical Study of Eighth Candidate Emerges Under the

Shots:   Sosei Heptares to receive $5M as milestones triggered by the dosing of the first subject in a clinical trial. In Jun’2019, Pfizer nominated the candidate for advancement and granted $3M as milestones   The companies collaborated in 2015 to develop therapies directed at up to ten GPCR targets across multiple therapeutic areas. The collaboration […]Read More

Mylan Launches Remdesivir Under the Brand Name Desrem for COVID-19

Shots: Mylan launches Desrem (remdesivir) addressing the unmet needs amid COVID-19. The drug is approved for the treatment of suspected or laboratory-confirmed incidences of COVID-19 in adults and children hospitalized with severe symptoms Mylan will manufacture Desrem in its state-of-the-art injectable facility in Bangalore, India, and other export markets where Mylan has received a license […]Read More

QIAGEN Releases QIAstat-Dx Test Kit as the First Syndromic Test

Shots: QIAGEN has started the shipment of its QIAstat-Dx Respiratory SARS-CoV-2 Panel test to the US for diagnosing the patients infected with COVID-19 under a new FDA’s policy, announced on Mar 16, 2020 The QIAstat-Dx test is a multiplexed nucleic acid test that assesses samples such as nasopharyngeal swabs obtained from individuals suspected of the […]Read More

Cyclica and AUM Biosciences Collaborate to Develop Novel Cancer Therapies

Shots: Cyclica to receive up front, milestones upon completion of specific stages for Project Nexus. AUM to get right to develop & commercialize therapies resulting from Project Nexus The collaboration leverages AUM’s drug development expertise including its biomarker-driven approach with Cyclica’s AI-augmented and structure-based platform, Ligand Design and Ligand Express The companies will design molecules […]Read More